Wnt5a analogs, such as Foxy-5 or Box-5, currently used in cancer research (Andersson et al., 2015; Zhan et al., 2017), may also serve as a treatment approach for orofacial clefts by targeting non-canonical Wnt signaling, warranting future research. This evidence concerns the gene WNT5A and orofacial cleft.